Table 1.
Demographic and clinical characteristics of the population.
| Variable | Overall population (n = 39) | RAS-mut (n = 26) |
NeoRAS-wt (n = 13) | P-value* |
|---|---|---|---|---|
| Age (median, range) | 63 (41-86) | 64 (41-86) | 64 (41-86) | .648 |
| ECOG PS (N, %) | .447 | |||
| 0 | 30 (76.9%) | 21 (80.8%) | 9 (69.2%) | |
| ≥1 | 9 (23.1%) | 5 (19.2%) | 4 (30.8%) | |
| Gender (N, %) | .482 | |||
| Female | 14 (35.9%) | 8 (30.8%) | 6 (46.2%) | |
| Male | 25 (64.1%) | 18 (69.2%) | 7 (53.8%) | |
| Primary tumor location (N, %) | .084 | |||
| Left colon | 13 (33.3%) | 11 (42.3%) | 2 (15.4%) | |
| Right colon | 18 (46.2%) | 12 (46.2%) | 6 (46.2%) | |
| Rectum | 8 (20.5%) | 3 (11.5%) | 5 (38.5%) | |
| WHO histological grade (N, %) | 1.000 | |||
| Low grade | 26 (66.7%) | 19 (73.1%) | 7 (53.8%) | |
| High grade | 4 (10.3%) | 3 (11.5%) | 1 (7.7%) | |
| Unknown | 9 (23.1%) | 4 (15.4%) | 5 (38.5%) | |
| Stage at diagnosis** (N, %) | .019 | |||
| II | 1 (2.6%) | 1 (3.8%) | 0 (0%) | |
| III | 15 (38.5%) | 6 (22.1%) | 9 (69.2%) | |
| IV | 23 (59.0%) | 19 (73.1%) | 4 (30.8%) | |
| Number of metastatic sites† (N, %) | .090 | |||
| 1 site | 23 (59.0%) | 18 (69.2%) | 5 (38.5%) | |
| ≥2 sites | 16 (41.0%) | 8 (30.8%) | 8 (61.5%) | |
| Metastatic sites (N, %) | ||||
| Liver | 25 (64.1%) | 19 (73.1%) | 6 (46.2%) | .157 |
| Lung | 12 (30.8%) | 7 (26.9%) | 5 (38.5%) | .486 |
| Peritoneum | 12 (30.8%) | 7 (26.9%) | 5 (38.5%) | .486 |
| Other | 9 (23.1%) | 4 (15.4%) | 5 (38.5%) | .256 |
| Type of surgery (N,%) | .158 | |||
| Primary tumor alone | 26 (66.7%) | 15 (57.7%) | 11 (84.6%) | |
| Primary tumor + metastasectomy | 12 (30.8%) | 10 (38.5%) | 2 (15.4%) | |
| Missing | 1 (2.6%) | 1 (3.8%) | 0 (0) | |
| Level of CEA at metastatic time (N, %) | .467 | |||
| <3.5ng/mL | 15 (38.5%) | 9 (34.6%) | 6 (46.2%) | |
| ≥3.5 ng/mL | 20 (51.3%) | 15 (57.7%) | 5 (38.5%) | |
| Missing | 4 (10.3%) | 2 (7.7%) | 2 (15.4%) | |
| Number of previous treatment lines before LB‡ (N,%) | .486 | |||
| <3 lines | 12 (30.8%) | 7 (26.9%) | 5 (38.5%) | |
| ≥3 lines | 27 (69.2%) | 19 (73.1%) | 8 (61.5%) | |
| Time to first progression of systemic treatment in mCRC§ | .320 | |||
| <11 months | 19 (48.7%) | 11 (42.3%) | 8 (61.5%) | |
| ≥11 months | 20 (51.3%) | 15 (57.7%) | 5 (38.5%) |
* p-value < .05 indicating statistically significant differences. ** Staging according to the American Joint Committee on Cancer (AJCC) 8th edition.
†Median of 1 site of metastases (min 1; max 4).
‡Median of 3 treatment lines before performing LB.
§Median of 11 months of response to first-line systemic treatment to mCRC.
Abbreviations: CEA: carcinoembryonic antigen; ECOG PS: Eastern Cooperative Oncology Group Performance Status; LB: liquid biopsy; mCRC: metastatic colorectal cancer; RAS-mut: RAS mutated; RAS-wt: RAS wild type; WHO: World Health Organization.